Eye disease in Behçet's syndrome

Behçet's Syndrome

Volumn , Issue , 2010, Pages 73-94

  Özyazgan, Yilmaz ^a   Bodaghi, Bahram ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Anti TNF alpha agents; Azathioprine; Blindness; Cataracts; Corticosteroids; Cyclosporine; Cystoid macular edema; Hypopyon; Interferon alpha; Iridocyclitis; Optic disk edema; Retinal vasculitis; Secondary glaucoma; Slit lamp; Synechia; Uveitis; Visual loss; Vitreous haze

Indexed keywords

EID: 84856826797     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-5641-5_5     Document Type: Chapter

References (80)

1. Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behçet's disease. N Engl J Med 341:1284-1291
2. Yazici H, Tüzün Y, Pazarli H et al (1984) Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 43:783-789 (Pubitemid 15190181)
3. Kazokoglu H, Onal S, Tugal-Tutkun I et al (2008) Demographic and clinical features of uveitis in tertiary centers in Turkey. Ophthalmic Epidemiol 15:285-293
4. Mishima S, Masuda K, Izawa Y et al (1979) Behçet's diesae in Japan: ophthalmologic aspects. Tr Am Ophthalmol Soc 76:225-279
5. Goto H, Mochizuki M, Yamaki K et al (2007) Epidemiological survey of intraocular inflammation in Japan. Jpn J Ophthalmol 51:41-44 (Pubitemid 46281230)
6. Rodriguez A, Calonge M, Pedroza-Serez M et al (1996) Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol 114:593-599 (Pubitemid 26136354)
7. Kural-Seyahi E, Fresko I, Seyahi N et al (2003) The long-term mortality and morbidity of Behçet's syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine 82:60-76 (Pubitemid 36139801)
8. Tugal-Tutkun I, Onal S, Altan Yaycioglu R et al (2004) Uveitis in Behçet's disease: an analysis of 880 patients. Am J Ophthalmol 138:373-380 (Pubitemid 39208563)
9. Tunc R, Keyman E, Melikoglu M, Fresko I, Yazici H (2002) Target organ associations in Turkish patients with Behçet's disease: a cross sectional study with exploratory factor analysis. J Rheumatol 29:2393-2396 (Pubitemid 35266032)
10. Nussenblatt RB, Whitcup SM, Paletsine AG (2004) Behçet's disease. In: Nussenblatt RB, Whitcup SM, Paletsine AG (eds) Uveitis: fundamentals and clinical practice. Mosby, Philadelphia, pp 350-371
11. Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509-516 (Pubitemid 41224845)
12. George RK, Chan CC, Whitcup SM et al (1997) Ocular immunopathology of Behçet's disease. Surv Ophthalmol 42:157-162
13. Ramsay A, Lightman S (2001) Hypopyon uveitis. Surv Ophthalmol 46:1-18 (Pubitemid 32781824)
14. Pazarli H, Ozyazgan Y, Aktunc T (1989) Clinical observations on hypopyon attacks of Behçet's disease in Turkey. In: Seventh international conference on Behçet's disease (abstracts), Rochester, MN, 14-15 Sept
15. Tugal-Tutkun I, Urgancioglu M, Foster CS (1995) Immunopathologic study of the conjunctiva in patients with Behçet's disease. Ophthalmology 102:1660-1668
16. Zamir E, Bodaghi B, Tugal-Tutkun I et al (2003) Conjunctival ulcers in Behçet's disease. Ophthalmology 110:1137-1141
17. Elgin U, Berker N, Batman A (2004) Incidence of secondary glaucoma in Behçet's disease. J Glaucoma 13:441-444 (Pubitemid 39546335)
18. Yalvaç IS, Sungur G, Turhan E et al (2004) Trabeculectomy with mitomycin-C in uveitic glaucoma associated with Behçet's disease. J Glaucoma 13:450-453 (Pubitemid 39546337)
19. Baer JC, Raizman MB, Foster CS (1990) Ocular Behçet's disease in the United States: clinical presentation and visual outcome in 29 patients. In: Masahiko U, Shigeaki O, Koki A (eds) Proceedings of the 5th international symposium on the immunology and immunopathology of the eye, Tokyo. Elsevier Science, New York, p 383
20. Ehrlich GE (1997) Vasculitis in Behçet's disease. Int Rev Immunol 14:81-88
21. Akman-Demir G, Serdaroglu P, Tasci B (1999) Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet's Study Group. Brain 122:2171-2182
22. Foster CS, Vitale AT (2002) Adamantiades-Behçet's disease. In: Foster CS, Vitale AT (eds) Diagnosis and treatment of uveitis. W. B. Saunders Company, Philadelphia, pp 632-652
23. Kacmaz RO, Kempen JH, Newcomb C et al, Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Group (2008)) Ocular inflammation in Behçet's disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol 146:828-836
24. Atmaca LS (1989) Fundus changes associated with Behçet's disease. Graefes Arch Clin Exp Ophthalmol 227:340-344 (Pubitemid 19180482)
25. Bozzoni-Pantaleoni F, Gharbiya M, Pirraglia MP et al (2001) Indocyanine gren angiographic findings in Behçet's disease. Retina 21:230-236 (Pubitemid 32531940)
26. Atmaca LS, Sönmez PA (2003) Fluorescein and indocyanine green angiography findings in Behçet's disease. Br J Ophthalmol 87:1466-1468 (Pubitemid 38010549)
27. Gedik S, Akova YA, Yilmaz G et al (2005) Indocyanine green and fundus fluorescein angiographic findings in patients with active ocular Behçet's disease. Ocul Immunol Inflamm 13:51-58 (Pubitemid 41702785)
28. Winter FC, Yukins RE (1966) The ocular pathology of Behçet's disease. Am J Ophthmol 62:257-262
29. Mullaney J, Collum LM (1985) Ocular vasculitis in Behçet's disease: a pathological and immunohistochemical study. Int Ophthalmol 7:183-191 (Pubitemid 15109412)
30. Hegab S, Al-Mutawa S (2000) Immunopathogenesis of Behçet's diseae. Clin Immunol 96:174-186
31. Atmaca LS, Batioglu F, Idil A (1996) Retinal and disc neovascularization in Behçet's disease and efficacy of laser photocoagulation. Graefes Arch Clin Exp Ophthalmol 234:94-99
32. El Belhadji M, Hamdani M, Laouissi N et al (1997) L'attente ophthalmologique dans la maladie d Behçet: a propos de 520 cas. J Fr Ophthalmol 20:592-598 (Pubitemid 27431877)
33. Ando K, Fujino Y, Hijikata K et al (1999) Epidemiological features and viusal prognosis of visual prognosis of Behçet's disease. Jpn J Ophthalmol 43:312-317 (Pubitemid 29329392)
34. Sakamoto M, Akazawa K, Nishioka Y et al (1995) Prognostic factors of vision in patients with Behçet's disease. Ophthalmology 102:317-321
35. Nussenblatt RB, Pelestine AG, Chan CC et al (1985) Standardization of vitreal inflammatory activity in intermediate and posteror uveitis. Ophthalmology 92:467-471 (Pubitemid 15034518)
36. Tugal-Tutkun I, Cingu K, Kir N, Yeniad B, Urgancioglu M, Gul A (2008) Use of laser flarecell photometry to quantify intraocular inflammation in patients with Behçet's uveitis. Graefes Arch Clin Exp Ophthalmol 246:1169-1177
37. Mamo JG (1970) The rate of visual loss in Behçet's disease. Arch Ophthalmol 84:451-452
38. Yazici H, Pazarli H, Barnes CG et al (1990) A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 322:281-285 (Pubitemid 20046329)
39. Hamuryudan V, Ozyazgan Y, Hizli N et al (1997) Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum 40:769-774 (Pubitemid 127744665)
40. BenEzra D, Cohen E, Chajek T et al (1988) Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome. Transplant Proc 20(3 Suppl 4):136-143
41. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G (1989) Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1:1093-1096 (Pubitemid 19128039)
42. Ozyazgan Y, Yurdakul S, Yazici H et al (1992) Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br J Ophthalmol 76:241-243
43. Hatemi G, Silman A, Bang D et al (2008) Management of Behçet's disease: a systematic literature review for the EULAR evidence based recommendations for the management of Behçet's disease. Ann Rheum Dis 68:1528-1534
44. Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti-TNF therapy in the management of Behçet's disease-review and basis for recommendations. Rheumatology (Oxford) 46:736-741 (Pubitemid 47061701)
45. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 358:295-296 (Pubitemid 32738970)
46. Tugal-Tutkun I, Mudun A, Urgancioglu M et al (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum 52:2478-2484 (Pubitemid 41117435)
47. Sfikakis PP, Kaklamanis PH, Elezoglou A et al (2004) Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet's disease. Ann Intern Med 140:404-406 (Pubitemid 38268925)
48. Ohno S, Nakamura S, Hori S et al (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 31:1362-1368 (Pubitemid 38879203)
49. Tabbara KF, Al-Hemidan AI (2008) Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet's disease. Am J Ophthalmol 146:845.e1-850.e1
50. Bodaghi B, Bui Quoc E, Wechsler B et al (2005) Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Ann Rheum Dis 64:962-964 (Pubitemid 40733930)
51. Niccoli L, Nannini C, Benucci M et al (2007) Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology (Oxford) 46:1161-1164 (Pubitemid 47050622)
52. Mushtaq B, Saeed T, Situnayake RD, Murray PI (2007) Adalimumab for sight-threatening uveitis in Behçet's disease. Eye 21:824-825 (Pubitemid 46909189)
53. van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM (2007) Adalimumab: a new modality for Behçet's disease? Ann Rheum Dis 66:565-566 (Pubitemid 46580490)
54. Melikoglu M, Fresko I, Mat C et al (2005) Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 32:98-105 (Pubitemid 40092599)
55. Durand JM, Soubeyrand J (1994) Interferon-alpha 2b for refractory ocular Behçet's disease. Lancet 344:333 (Pubitemid 24230309)
56. Feron EJ, Rothova A, van Hagen PM, Baarsma GS, Suttorp-Schulten MS (1994) Interferonalpha 2b for refractory ocular Behçet's disease. Lancet 343:1428 (Pubitemid 24167522)
57. Pivetti-Pezzi P, Accorinti M, Pirraglia MP, Priori R, Valesini G (1997) Interferon alpha for ocular Behçet's disease. Acta Ophthalmol Scand 75:720-722 (Pubitemid 28102747)
58. Sánchez Román J, Pulido Aguilera MC, Castillo Palma MJ et al (1996) [The use of interferon alfa-2r in the treatment of autoimmune uveitis (primary or associated with Behçet's disease)]. Rev Clin Esp 196:293-298
59. Kötter I, Eckstein AK, Stübiger N, Zierhut M (1998) Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study. Br J Ophthalmol 82:488-494
60. Kotter I, Deuter C, Stubiger N, Zierhut M (2005) Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet's disease: focusing more on IFN. J Rheumatol 32:1633
61. Kötter I, Vonthein R, Zierhut M et al (2004) Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet's disease: results of an open 4-center trial. Semin Arthritis Rheum 33:311-319 (Pubitemid 38496040)
62. Kötter I, Zierhut M, Eckstein A et al (2003) Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet's disease with sight-threatening retinal vasculitis. Adv Exp Med Biol 528:521-523
63. Kötter I, Zierhut M, Eckstein AK et al (2003) Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87:423-431 (Pubitemid 36399030)
64. Bodaghi B, Gendron G, Wechsler B et al (2007) Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 91:335-339 (Pubitemid 46586530)
65. Krause L, Turnbull JR, Torun N, Pleyer U, Zouboulis CC, Foerster MH (2003) Interferon alfa-2a in the treatment of ocular Adamantiades- Behçet's disease. Adv Exp Med Biol 528:511-519
66. Tugal-Tutkun I, Güney-Tefekli E, Urgancioglu M (2006) Results of interferon-alfa therapy in patients with Behçet's uveitis. Graefes Arch Clin Exp Ophthalmol 244:1692-1695 (Pubitemid 44830831)
67. Gueudry J, Wechsler B, Terrada C et al (2008) Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet's disease. Am J Ophthalmol 146:837.e1-844.e1
68. Buggage RR, Levy-Clarke G, Sen HN et al (2007) A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul Immunol Inflamm 15:63-70 (Pubitemid 46897689)
69. Atmaca LS, Yalcindag FN, Ozdemir O (2007) Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Behçet's disease. Graefes Arch Clin Exp Ophthalmol 245:451-456 (Pubitemid 46404010)
70. Karacorlu M, Mudun B, Ozdemir H, Karacorlu SA, Burumcek E (2004) Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behçet's disease. Am J Ophthalmol 138:289-291 (Pubitemid 39037437)
71. Ohguro N, Yamanaka E, Otori Y, Saishin Y, Tano Y (2006) Repeated intravitreal triamcinolone injections in Behçet's disease that is resistant to conventional therapy: one-year results. Am J Ophthalmol 141:218-220 (Pubitemid 43016208)
72. Oueghlani E, Pavesio CE (2008) Intravitreal triamcinolone injection for unresponsive cystoid macular oedema in probable Behçet's disease as an additional therapy. Klin Monatsbl Augenheilkd 225:497-499 (Pubitemid 352016496)
73. Tuncer S, Yilmaz S, Urgancioglu M, Tugal-Tutkun I (2007) Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet's disease. J Ocul Pharmacol Ther 23:395-401 (Pubitemid 350195065)
74. Saidel MA, Berreen J, Margolis TP (2005) Cytomegalovirus retinitis after intravitreous triamcinolone in an immunocompetent patient. Am J Ophthalmol 140:1141-1143 (Pubitemid 41821313)
75. Mirshahi A, Namavari A, Djalilian A, Moharamzad Y, Chams H (2009) Intravitreal bevacizumab (Avastin) for the treatment of cystoid macular edema in Behçet's disease. Ocul Immunol Inflamm 17:59-64
76. Erdurman FC, Durukan AH, Mumcuoglu T, Hürmeric V (2009) Intravitreal bevacizumab treatment of macular edema due to optic disc vasculitis. Ocul Immunol Inflamm 17:56-58
77. Elgin U, Berker N, Batman A, Soykan E (2007) Nd:YAG laser iridotomy in the management of secondary glaucoma associated with Behçet's disease. Eur J Ophthalmol 17:191-195 (Pubitemid 46918104)
78. Elgin U, Berker N, Batman A, Soykan E (2007) Trabeculectomy with mitomycin C in econdary glaucoma associated with Behçet's disease. J Glaucoma 16:68-72 (Pubitemid 46114777)
79. Berker N, Soykan E, Elgin U, Ozkan SS (2004) Phacoemulsification cataract extraction and intraocular lens implantation in patients with Behçet's disease. Ophthalmic Surg Lasers Imaging 35:215-218 (Pubitemid 38621454)
80. Kadayifcilar S, Gedik S, Eldem B, Irkec M (2002) Cataract surgery in patients with Behçet's disease. J Cataract Refract Surg 28:316-320 (Pubitemid 34132488)